Newsroom

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus’ multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platf...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These results will be...

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared positive updated results from inMMyCAR, the ongoing first-in-human Phase 1 study of KLN-1010 in patients with relapsed and refractory multiple myeloma (RRMM), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Fourteen additional patients have been dosed since first clinical data were reported at the American Societ...

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer Shares New Findings for NUBEQA for Cognitive Decline in Men with aPC Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial...

WILMINGTON, Del.--(BUSINESS WIRE)--  Cruciale frontMIND-studie van Incyte heeft aangetoond dat de combinatie van tafasitamab (Monjuvi®/Minjuvi®) de progressievrije overleving significant verlengde en het risico op ziekteprogressie of overlijden met 25% verlaagde bij patiënten met eerder onbehandeld, hoogrisico DLBCL. Incyte (Nasdaq: INCY) heeft vandaag positieve resultaten bekendgemaakt van de cruciale Fase 3 frontMIND-studie, waarin de werkzaamheid en veiligheid werd beoordeeld van tafasitamab...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients...

WILMINGTON, Delaware--(BUSINESS WIRE)--  El ensayo fundamental frontMIND de Incyte demostró que la combinación con tafasitamab (Monjuvi®/Minjuvi®) prolongó significativamente la supervivencia libre de progresión, lo que reduce en un 25 % el riesgo de progresión de la enfermedad o muerte en pacientes con linfoma difuso de células B grandes de alto riesgo no tratado previamente Incyte (Nasdaq:INCY) anunció hoy resultados positivos del ensayo fundamental frontMIND fase 3, que evalúa la eficacia y...

WILMINGTON, Delaware--(BUSINESS WIRE)--  frontMIND, lo studio clinico cardine di Incyte ha dimostrato come la combinazione tafasitamab (Monjuvi®/Minjuvi®) sia in grado di prolungare notevolmente la sopravvivenza libera da progressione, riducendo il rischio di progressione della malattia o di decesso del 25% in pazienti affetti da DLBCL ad alto rischio precedentemente non trattato Incyte (Nasdaq:INCY) ha annunciato oggi i risultati positivi ottenuti dallo studio clinico cardine di Fase 3 frontMI...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and breast cancer. The data are being presented at the 2026 American Soc...

SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”), the world’s leading owner and operator of LPG vessels, announces that it has signed a contract for the construction of eight 90’cbm Panamax Very Large Gas Carriers (VLGCs), for a total consideration of about US$940 million, subject to the final technical specifications. The newbuildings are expected to be delivered sequentially from the start of 2029 until the second quarter of 2030. “This newbuil...